Europe’s Heartbeat: A Turning Point in Cardiovascular Prevention?

A vision anchored in prevention and early detection

At its core, the plan prioritises prevention over crisis management, a pivot of significance for clinicians accustomed to late‑stage intervention paradigms. The European Commission has set ambitious targets, including a 25% reduction in premature cardiovascular deaths by 2035, along with improved coverage of key risk factor screening such as blood pressure, cholesterol and blood glucose testing.²

Prevention under the plan spans lifestyle measures, from tobacco control and physical activity promotion to healthier diets, as well as vaccination strategies, recognising the role of infections like influenza and pneumococcal disease in precipitating cardiac events.³ But it is the proposed EU Protocol on Health Checks that may prove transformational for clinical practice. This framework seeks to harmonise cardiovascular risk screening across countries, fostering more consistent early detection of at-risk individuals and earlier initiation of targeted interventions.²

This focus resonates with a broad coalition of civil society and professional groups, such as JA PreventNCT, who have welcomed the plan’s prevention emphasis, noting its alignment with strategies to address both individual and societal risk factors for CVD and non‑communicable diseases more broadly.⁴

Implementation challenges and critiques

Notwithstanding widespread support for the plan’s goals, some stakeholders have expressed reservations. Critics argue that it lacks binding measures and clear regulatory mechanisms, particularly in areas such as nutrition policy, where legislative tools to reduce exposure to high-fat, high-sugar, and high-salt foods were discussed but not adopted.^2,5 Consumer advocacy groups have also pointed to gaps in measurable commitments and protections, highlighting the tension between ambition and enforceability in EU health strategies.³

Moreover, while technological innovation and digital tools are flagged as enablers of personalised risk prediction, many clinicians caution that deploying artificial intelligence and data platforms will require robust governance, interoperability and clinician oversight to ensure both clinical utility and trust.

A nod to genetic and lifelong risk

One of the most noteworthy aspects of the joint response from leading scientific and patient advocacy groups, FH Europe Foundation (FHEF), European Atherosclerosis Society (EAS), and the Lp(a) International Task Force, is their emphasis on the plan’s explicit recognition that cardiovascular risk can be genetic and lifelong.^6,7

Traditionally, risk stratification and preventive efforts have centred on lifestyle factors and adult risk profiles. The plan’s acknowledgment of conditions like familial hypercholesterolaemia (FH) and elevated lipoprotein(a) (Lp[a]), both of which are often underdiagnosed and present from birth, represents a meaningful expansion of cardiovascular prevention discourse.^6,7

In their joint statement, FHEF, EAS and the Lp(a) International Task Force urged that screening and health checks be broad, systematic and start early in life, moving beyond adult-only paradigms. This aligns with a growing consensus that lipid abnormalities should be identified and managed before clinical disease manifests, an approach which has been long championed in clinical guidelines and genetic risk literature.^6,7

Their collective position also highlights the need for family-based and reverse cascade testing, integrated digital tools and risk profiles that include low-density lipoprotein cholesterol, Lp(a) and triglyceride measurements. Such comprehensive profiling could enable clinicians to deliver personalised, precise prevention before irreversible arterial damage occurs.^6,7

Looking forward: From strategy to impact

For European healthcare professionals, the plan offers both a strategic framework and a call to action. The challenge now lies in implementation: translating high-level commitments into national health policies, clinical pathways and everyday practice. Success will hinge on collaboration between clinicians, researchers, policymakers and patient advocates, as well as investment in data, education and equity-focused health systems.

In an era where precision medicine and public health are converging, the plan has the potential to be more than a policy document: it could serve as a catalyst for meaningful reductions in cardiovascular risk and mortality across the EU. Its real measure will be in the lives changed and the lives saved.